Beiersdorf's Stock Relies on Dermatology Division for Growth

Beiersdorf sees strong growth in its Aquaphor/Eucerin derma segment, offsetting Nivea's stagnation and near-term sales headwinds, with shares at a 52-week low.

The strategic picture at Beiersdorf can be summarized by two contrasting trends: robust expansion for Aquaphor and stagnation for Nivea. A recent product launch underscores this shift. On March 18, the company's U.S. subsidiary introduced the "Aquaphor Baby Sensitive Lotion," the brand's first baby lotion, now available nationwide at major retailers. While a single product, this move is indicative of a broader strategic realignment within the Hamburg-based consumer goods group.

First Quarter Headwinds and Annual Outlook

The near-term operating environment presents challenges. For the first quarter of 2026, Beiersdorf anticipates a slight organic sales decline. This forecast is attributed to disruptions in U.S. retail channels and continued softness in the Chinese travel retail sector. Looking at the full year, management has guided the market to expect flat to modest growth. The company also projects its EBIT margin will come in slightly below the prior year's level of 14.0 percent.

This uncertainty is clearly reflected in the company's share price performance. The equity currently trades at its 52-week low of €73.34, representing a decline of approximately 44 percent from its peak in March 2025.

Dermatology Segment Powers Forward

Amidst this backdrop, the Derma division stands out as the primary growth engine. Comprising the Aquaphor and Eucerin brands, this segment achieved a record €1.5 billion in sales during 2025. This performance was fueled by double-digit growth rates and a targeted expansion strategy across North America, Europe, and emerging markets. Key patented ingredients, such as Thiamidol and Epicelline, are cited as critical factors that differentiate the company's products from competitors.

Nivea's Portfolio Reset

In stark contrast, the flagship Nivea brand significantly lagged in the same period, posting organic sales growth of just 0.9 percent. In response, corporate leadership has initiated a portfolio repositioning for Nivea, with a renewed emphasis on core body care and deodorant categories.

The central question for investors is whether the strong momentum in the dermatology business can sufficiently compensate for the margin pressures and slower growth of the Nivea brand in the medium term. The forthcoming release of the complete first-quarter financial results will provide the next significant data point.